Completed PHASE1 INTERVENTIONAL 1-arm NCT00455052

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

Sponsor: Mersana Therapeutics

Conditions Non-small Cell Lung Cancer Small Cell Lung Cancer

Interventions XMT-1001

Updated 7 times since 2017 Last updated: Jan 29, 2018 Started: Mar 31, 2011 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Non-small Cell Lung Cancer and Small Cell Lung Cancer and is currently completed. Mersana Therapeutics leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2018 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Feb 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mersana Therapeutics

Data source: Mersana Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Denver, United States , Greenville, United States , Indianapolis, United States , Las Vegas, United States , New York, United States , Norfolk, United States , Scottsdale, United States , Spokane, United States , Springfield, United States and 2 more locations